YUVIWEL

all catalysts(0)

nothing on the calendar yet

News(5)

• 5 biotechs braving the commercial waters with product launches
  A growing number of biotechs are entering the market with newly launched medicines, a pattern indicative of “improving capital markets,” according to Jefferies’ Andrew Tsai.
  biospace · 17d ago
• Novo walks away from $285M pact to develop monthly GLP-1 obesity drug with Ascendis
  Novo’s attempted rebrand got off to a shaky start this week with the news that the pharma had walked away from a $285 million biobucks pact to develop a monthly weight loss drug after less than two…
  fiercebiotech · 18d ago
• Teva claims success in celiac study; BioMarin, Ascendis settle patent dispute
  Teva believes the therapy has “pipeline-in-a-product” potential. Elsewhere, a high-stakes trial was paused and GSK advanced a competitor to Moderna’s flu shot.
  biopharma_dive · 1mo ago
• Biomarin nabs big royalties in achondroplasia patent settlement with Ascendis
  Biomarin has granted Ascendis a non-exclusive, worldwide license to use navepegritide, the active ingredient in the latter company’s recently approved achondroplasia drug Yuviwel, in exchange for 1…
  biospace · 1mo ago
• BioMarin axes asset from $270M Inozyme takeover, ending run in rare metabolic indication
  BioMarin’s discontinued drug showed biomarker benefits in a Phase 3 study for ENPP1 deficiency but these failed to translate to clinical improvements.
  biospace · 1mo ago